Microarray News and Research

RSS

US-LACRN selects Agilent gene expression microarrays for major breast cancer study

Agilent Technologies Inc. today announced that the United States-Latin American Cancer Research Network has selected Agilent Gene Expression microarrays and associated instruments for a major study of breast cancer in five Latin American nations.

21 Apr 2011

New method allows single microchip to screen tens of thousands of genes simultaneously

RNA interference technology, which is used in cell biology, has revolutionised functional research of the gene products in the last ten years. VTT Technical Research Centre of Finland has developed a method which allows a single microchip to be used to screen the functions of tens of thousands of genes simultaneously by means of RNA interference.

20 Apr 2011

Antibodies to non-human sugar molecule may be useful for early detection of cancer

Researchers at the University of California, San Diego School of Medicine say antibodies to a non-human sugar molecule commonly found in people may be useful as a future biomarker for predicting cancer risk, for diagnosing cancer cases early and, in sufficient concentration, used as a treatment for suppressing tumor growth.

20 Apr 2011

SQI enters clinical validation agreement with University North Carolina Kidney Center for Vasculitis Assay

SQI Diagnostics Inc., a medical systems automation company focused on evolving laboratory-based autoimmune biomarker testing, today announced it entered into a clinical validation agreement with University North Carolina Kidney Center, Chapel Hill, to evaluate SQI's new multiplexed, automated approach for biomarker detection in vasculitis.

15 Apr 2011

Keryx KRX-0401 data in colorectal cancer, multiple myeloma presented at AACR meeting

Keryx Biopharmaceuticals, Inc. today announced that two posters on KRX-0401 were presented at the 102nd annual meeting of the American Association for Cancer Research currently ongoing at the Orange County Convention Center in Orlando, Florida. Perifosine, the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, is currently in Phase 3 clinical trials for refractory advanced colorectal cancer and multiple myeloma.

6 Apr 2011

New amniochip to detect 150 genetic genetic syndromes

Genetadi Biotech has presented to the scientific community - meeting at the XXVI National Congress on Human Genetics held in Murcia - a prenatal diagnostic device based on amniocentesis.

6 Apr 2011

Aeterna Zentaris presents two posters on perifosine at AACR meeting

Aeterna Zentaris Inc. today announced that two posters on its lead anticancer agent, perifosine, were presented at the 102nd annual meeting of the American Association for Cancer Research currently held at the Orange County Convention Center in Orlando, Florida.

5 Apr 2011

New computer-based system can distinguish similar secondary tumours

A new computer-based system discussed in the International Journal of Healthcare Technology and Management can distinguish between apparently similar secondary tumours and allow a cancer specialist to trace the metastases back to the site of the original cancer in the patient's body.

5 Apr 2011

PGXL to utilize AutoGenomics' automated INFINITI analyzer for personalized medicine applications

PGXL Labs, an internationally recognized pioneer in personalized medicine testing, announced today that it has established a collaborative partnership with AutoGenomics, Inc. wherein they will utilize the automated INFINITI® analyzer for several different personalized medicine applications.

1 Apr 2011

Individualized dentritic cell vaccine may increase survival time in patients with glioblastoma

A dendritic cell vaccine personalized for each individual based on the patient's own tumor may increase median survival time in those with a deadly form of brain cancer called glioblastoma, an early phase study at UCLA's Jonsson Comprehensive Cancer Center has found.

18 Mar 2011

Personalized dendritic cell vaccine may increase median survival in mesenchymal glioblastoma patients

17 Mar 2011

Skyline Diagnostics launches unique test to detect patients with AML

Each year over eight million people die of cancer worldwide. Patients' chances of survival vary widely: depending on the type of cancer involved, the stage at which it is diagnosed and the speed with which appropriate treatment is launched.

17 Mar 2011

Ingenuity announces new features to support RNA-Seq workflows, microRNA research in IPA

Ingenuity Systems, a leading provider of information and analytics solutions for life science researchers, today announced new features to support RNA-Sequencing workflows and microRNA research in IPA.

15 Mar 2011

NIH awards InDevR $3 million Phase II SBIR grant for influenza-related research

InDevR announced today that it has been awarded a Phase II Small Business Innovation Research grant from the National Institutes of Health in the amount of $3 million over the next 3 years.

11 Mar 2011

New technique may find 'hidden' receptors in nerve cells

Scientists at The Scripps Research Institute and University of Pennsylvania have found a way to uncover potential drug targets that have so far remained hidden from researchers' view.

11 Mar 2011

Autoimmune response mediated by T lymphocytes may play vital role in pathogenesis of biliary atresia

Biliary atresia (BA) is an inflammatory obliterative cholangiopathy with unknown etiology, leading to progressive fibrosis and cirrhosis. Microarray technology, emerged as an indispensable research tool for gene expression profiling, has been used to study the mechanism underlying BA, and allows the simultaneous analysis of thousands of transcripts within a single experiment.

9 Mar 2011

Affymetrix releases complete genotyping data set on its website

Affymetrix, Inc. today announced the release of a complete data set of 5 million variants on its website.

3 Mar 2011

Agilent Technologies acquires Lab901

Agilent Technologies Inc. today announced it has acquired Lab901, a leading electrophoresis equipment and consumables company based in Edinburgh, U.K. The company's automated electrophoresis products are used for DNA, RNA and protein analysis. Financial details of the acquisition were not disclosed.

28 Feb 2011

FDA clears Agendia's breast cancer recurrence assay

Agendia, a world leader in molecular cancer diagnostics, today announced that the company has received its fifth U.S. Food and Drug Administration clearance for MammaPrint, its widely used breast cancer recurrence assay.

23 Feb 2011

New DNA microarray detects genetic changes differentiating cancer patients from healthy individuals

A group of researchers led by scientists from the Virginia Bioinformatics Institute at Virginia Tech have developed a new technology that detects distinct genetic changes differentiating cancer patients from healthy individuals and could serve as a future cancer predisposition test.